Journal article
Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan
Frontiers in oncology, Vol.14, 1369126
04/01/2024
DOI: 10.3389/fonc.2024.1369126
PMCID: PMC11091385
PMID: 38746680
Abstract
BackgroundThis study aims to evaluate real-world (rw) outcomes of immunotherapy (IO) for advanced stage NSCLC at King Hussein Cancer Center (KHCC) in Jordan.MethodsAdvanced stage NSCLC patients who received IO at KHCC between 2017 and 2022 were included. The data were retrospectively collected. PFS and OS were estimated for patients with ECOG performance status (ECOG PS) 0-1. Cox regression analyzed predictors of OS in first-line (1L) IO, regardless of performance status.ResultsThe total number of patients included was 244. Out of those, 160 (65%), 67 (28%), and 17 (7%) patients received IO as 1L, second-line (2L), or third-line or beyond (3L or beyond), respectively. The median age for all patients was 59 years. Male were 88%, and 77% were smokers. The median follow-up time was 12.5 months. The median PFS and OS for 1L IO were 7 [95% CI 5.8 – 10.3] and 11.8 [95% CI 8.8 – 14.4], months, respectively. In the first 3 months after starting 1L IO, 34/160 (21%) patients had died. For those who survived beyond 3 months after starting 1L IO, the median PFS and OS were 11.3 [95% CI 8.3 – 16.5] and 15.4 [95% CI 13.2 – 21] months, respectively. In the Cox regression model of 1L IO patients with any performance status, ECOG PS 2 was predictive of worse OS compared to ECOG PS 0-1 (p= 0.005).ConclusionThis real-world study of advanced-stage NSCLC patients treated with immunotherapy at KHCC reveals outcomes that fall short of those anticipated from clinical trials. The inclusion of Middle Eastern patients in lung cancer trials is essential to ensure adequate representation of various ethnicities in clinical research.
Details
- Title: Subtitle
- Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan
- Creators
- Taher Abu Hejleh - University of IowaKarim AlSawalha - King Hussein Cancer CenterSufian Abdel Hafiz - King Hussein Cancer CenterTamer Al-Batsh - King Hussein Cancer CenterRoaa Abu Hejleh - King Hussein Cancer CenterSameer Yaser - King Hussein Cancer CenterHusam Abu Jazar - King Hussein Cancer CenterJamal Khader - King Hussein Cancer CenterAnoud Alnsour - King Hussein Cancer CenterIssa Mohamad - King Hussein Cancer CenterRiad Abdel Jalil - King Hussein Cancer CenterAhmad Abu-Shanab - King Hussein Cancer CenterAzza Gharaibeh - King Hussein Cancer CenterMohammad Abu Shattal - King Hussein Cancer CenterAkram Alibraheem - King Hussein Cancer CenterHussam Haddad - King Hussein Cancer CenterNaser Mahmoud - King Hussein Cancer CenterShadi Obeidat - King Hussein Cancer CenterMohammed J. Al-Jaghbeer - King Hussein Cancer CenterMuhammad Furqan - University of IowaAlessio Cortellini - Imperial College LondonVamsidhar Velcheti - New York UniversityKamal Al-rabi - King Hussein Cancer Center
- Resource Type
- Journal article
- Publication Details
- Frontiers in oncology, Vol.14, 1369126
- Publisher
- Frontiers Media S.A
- DOI
- 10.3389/fonc.2024.1369126
- PMID
- 38746680
- PMCID
- PMC11091385
- eISSN
- 2234-943X
- Language
- English
- Date published
- 04/01/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984622897702771
Metrics
37 Record Views